AndrostenediolCAS# 521-17-5 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 521-17-5 | SDF | Download SDF |
| PubChem ID | 10634 | Appearance | Powder |
| Formula | C19H30O2 | M.Wt | 290.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol | ||
| SMILES | CC12CCC3C(C1CCC2O)CC=C4C3(CCC(C4)O)C | ||
| Standard InChIKey | QADHLRWLCPCEKT-LOVVWNRFSA-N | ||
| Standard InChI | InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Androstenediol Dilution Calculator
Androstenediol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.4435 mL | 17.2176 mL | 34.4353 mL | 68.8705 mL | 86.0882 mL |
| 5 mM | 0.6887 mL | 3.4435 mL | 6.8871 mL | 13.7741 mL | 17.2176 mL |
| 10 mM | 0.3444 mL | 1.7218 mL | 3.4435 mL | 6.8871 mL | 8.6088 mL |
| 50 mM | 0.0689 mL | 0.3444 mL | 0.6887 mL | 1.3774 mL | 1.7218 mL |
| 100 mM | 0.0344 mL | 0.1722 mL | 0.3444 mL | 0.6887 mL | 0.8609 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Dromostanolone propionate
Catalog No.:BCC8954
CAS No.:521-12-0
- Mestanolone
Catalog No.:BCC9022
CAS No.:521-11-9
- 2-Hydroxy-7-O-methylscillascillin
Catalog No.:BCN5659
CAS No.:52096-50-1
- H-Val-pNA
Catalog No.:BCC3139
CAS No.:52084-13-6
- NCS-382
Catalog No.:BCC6794
CAS No.:520505-01-5
- Isoschaftoside
Catalog No.:BCN3011
CAS No.:52012-29-0
- Medroxyprogesterone
Catalog No.:BCC5231
CAS No.:520-85-4
- Echimidine
Catalog No.:BCN1967
CAS No.:520-68-3
- Rosmarinine
Catalog No.:BCN2124
CAS No.:520-65-0
- Spartioidine
Catalog No.:BCN2134
CAS No.:520-59-2
- Spectabiline
Catalog No.:BCN2098
CAS No.:520-55-8
- Psilocin
Catalog No.:BCC6168
CAS No.:520-53-6
- Stanolone
Catalog No.:BCC9153
CAS No.:521-18-6
- Bilobetin
Catalog No.:BCN5661
CAS No.:521-32-4
- Sciadopitysin
Catalog No.:BCN5662
CAS No.:521-34-6
- Cannabinol
Catalog No.:BCN7968
CAS No.:521-35-7
- Pedicin
Catalog No.:BCN4845
CAS No.:521-51-7
- Vulpic acid
Catalog No.:BCN6546
CAS No.:521-52-8
- Physcion
Catalog No.:BCN5663
CAS No.:521-61-9
- Frangulin A
Catalog No.:BCC8174
CAS No.:521-62-0
- Cinnamoylcocaine
Catalog No.:BCN1429
CAS No.:521-67-5
- Broxyquinoline
Catalog No.:BCC4642
CAS No.:521-74-4
- Karanjin
Catalog No.:BCN8370
CAS No.:521-88-0
- 2,4-Dihydroxy-6-methoxy-3-formylacetophenone
Catalog No.:BCN1430
CAS No.:52117-67-6
The Non-Aromatic Delta5-Androstenediol Derivative of Dehydroepiandrosterone Acts as an Estrogen Agonist in Neonatal Rat Osteoblasts through an Estrogen Receptor alpha-related Mechanism.[Pubmed:30580653]
Endocr Res. 2018 Dec 24:1-16.
PURPOSE: It has been proposed that DHEA influences bone formation through, bioconversion to 17beta-estradiol; however, DHEA is converted to Delta5-Androstenediol (Delta5-Adiol), a metabolite with estrogenic potential involved in diverse biological process. To gain new insight into the role of Delta5-Adiol in bone cells, we examined DHEA and Delta5-Adiol effects in neonatal rat and human hFOB1.19 osteoblasts. METHODS: Osteoblast activity was assessed by analyzing proliferation, alkaline phosphatase activity, and expression of OSX and ALPL. We also examined binding affinities for osteoblast-ER and transcriptional activation of human (h)ERalpha, hERbeta or hAR in U2-OS cells. RESULTS: The most striking finding was that Delta5-Adiol had greater stimulatory effect than DHEA on rat osteoblast proliferation and differentiation, as well as ALPL expression in human osteoblasts. Interestingly, the Delta5-Adiol or DHEA-induced effects were not precluded with letrozole or trilostane, consistent with bioconversion of DHEA to Delta5-Adiol due to elevated expression of Hsd17b1 in neonatal rat osteoblasts, suggesting a high level of 17beta-hydroxysteroid dehydrogenase type 1 activity. Conversely, Delta5-Adiol and DHEA-induced proliferative effects were inhibited with ICI 182780 alone or combined with trilostane, which correlates with the higher binding affinity of Delta5-Adiol for ER compared to DHEA. Furthermore, Delta5-Adiol showed a greater relative agonist activity for hERalpha than for hERbeta or hAR. CONCLUSION: This study is the first to show that a bioactive DHEA derivative stimulates E2-dependent osteoblast activities, including proliferation and differentiation in rat and human osteoblasts, through ERalpha-related mechanisms.
